Atlas Trials

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

Clinical trial NCT04137640 · UNKNOWN

Trial details

NCT number
NCT04137640
Sponsor
Shengjing Hospital
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Breast Cancer
Start date
2021-07-19
Primary completion
2025-11-30
Enrollment
152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.